The MERLIN__001 trial confirms the Merlin test's effectiveness in predicting SLNB status in melanoma patients, involving 1686 participants across nine US academic sites. The CP-GEP Merlin model, developed by Mayo Clinic and SkylineDx, offers a non-invasive method to identify high-risk melanoma patients, potentially reducing unnecessary SLNB procedures. Results from Society...